Rising awareness regarding obesity and diabetes management is supporting demand for innovative delivery methods
Access crucial information at unmatched prices
The effectiveness of once-daily subcutaneous liraglutide administration for weight loss management in adults was established in five large-scale randomized multicentre phase 3 trials [49,50,51,52,53], four of which were part of the SCALE program (Satiety and Clinical AdiposityLiraglutide Evidence in nondiabetic and diabetic individuals), leading to its approval at a dose of 3.0 mg subcutaneous once-daily (weekly increased from 0.6 mg to 3 mg/day)
The goal is better metabolic health, better function, and a body that can sustain the result
Niacin: Too much over the long term may lead to liver damage
Months 46 Many patients reach a maintenance dose or the highest tolerated dose